Bridgeway Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Bridgeway Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,700	Closed	-$391K	–	1252
2026 Q1	$391K	Hold	26,700	–	–	0.01%	868
2025 Q4	$206K	Sell	26,700 -40,000	-60%	-$315K	﹤0.01%	1012
2025 Q3	$492K	Hold	66,700	–	–	0.01%	807
2025 Q2	$267K	Buy	66,700 +25,400	+62%	+$92.4K	0.01%	894
2025 Q1	$131K	Hold	41,300	–	–	﹤0.01%	994
2024 Q4	$221K	Sell	41,300 -86,000	-68%	-$642K	﹤0.01%	984
2024 Q3	$672K	Hold	127,300	–	–	0.01%	783
2024 Q2	$232K	Sell	127,300 -97,000	-43%	-$181K	0.01%	1023
2024 Q1	$399K	Buy	224,300 +75,000	+50%	+$157K	0.01%	982
2023 Q4	$263K	Hold	149,300	–	–	0.01%	1081
2023 Q3	$218K	Buy	149,300 +40,000	+37%	+$84.6K	0.01%	1083
2023 Q2	$250K	Sell	109,300 -50,000	-31%	-$104K	0.01%	1084
2023 Q1	$145K	Hold	159,300	–	–	﹤0.01%	1167
2022 Q4	$135K	Hold	159,300	–	–	﹤0.01%	1169
2022 Q3	$130K	Hold	159,300	–	–	﹤0.01%	1224
2022 Q2	$158K	Hold	159,300	–	–	﹤0.01%	1140
2022 Q1	$261K	Sell	159,300 -65,000	-29%	-$119K	0.01%	1119
2021 Q4	$541K	Buy	224,300 +65,000	+41%	+$252K	0.01%	960
2021 Q3	$771K	Sell	159,300 -50,000	-24%	-$148K	0.01%	906
2021 Q2	$559K	Buy	209,300 +5,000	+2%	+$13.8K	0.01%	1035
2021 Q1	$629K	Buy	204,300 +70,600	+53%	+$255K	0.01%	1032
2020 Q4	$476K	Hold	133,700	–	–	0.01%	965
2020 Q3	$536K	Hold	133,700	–	–	0.01%	861
2020 Q2	$364K	Hold	133,700	–	–	0.01%	967
2020 Q1	$282K	Hold	133,700	–	–	0.01%	949
2019 Q4	$727K	Buy	+133,700	New	+$468K	0.01%	826
2019 Q2	–	Sell	-89,000	Closed	-$358K	–	1336
2019 Q1	$358K	Buy	89,000 +9,400	+12%	+$39.7K	﹤0.01%	1118
2018 Q4	$292K	Sell	79,600 -25,000	-24%	-$170K	﹤0.01%	1132
2018 Q3	$897K	Buy	104,600 +19,600	+23%	+$196K	0.01%	927
2018 Q2	$933K	Hold	85,000	–	–	0.01%	898
2018 Q1	$980K	Hold	85,000	–	–	0.01%	849
2017 Q4	$881K	Hold	85,000	–	–	0.01%	886
2017 Q3	$1.35M	Buy	+85,000	New	+$1.18M	0.02%	734

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bridgeway Capital Management's CRVS Position: Q2 2026 in Review

Bridgeway Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 26,700 shares — an estimated $391K sold.

Bridgeway Capital Management first reported a position in CRVS in Q3 2017 and held it in 33 quarters. The position peaked at $1.35M in Q3 2017. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Bridgeway Capital Management reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bridgeway Capital Management sold 26,700 Corvus Pharmaceuticals shares in Q2 2026, an estimated $391K.
Bridgeway Capital Management first reported a position in Corvus Pharmaceuticals in Q3 2017 and held it in 33 quarters.
Bridgeway Capital Management's Corvus Pharmaceuticals position peaked at $1.35M in Q3 2017.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.